 |
43 Diseases |  |
1 Trial |
|
1 Trial |  |
90 News |  |
| 12» |
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial. (Hall A; Poster Bd #: 179) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1315;
P2
Despite the exploratory nature of this observation, this is the first significant and profound long-term survival benefit of an anti-cancer vaccine in breast cancer patients reported to date. Additional studies are needed to understand in more detail the underlying mechanisms, and the optimal use of cancer vaccines in breast cancer treatment.
- || Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Review, Journal: Liposomal formulations for lung cancer treatment in the last two decades: a systematic review. (Pubmed Central) - Aug 7, 2022
This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patients' cohort considering more responsive subgroups would be beneficial to strengthen the scientific and clinical evidence of the results herein reported.
- || Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Clinical, Journal: Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). (Pubmed Central) - Feb 25, 2022
The objective of this analysis was to compare these favorable outcome data with recent results from the LICC trial investigating the antigen-specific cancer vaccine tecemotide (L-BLP25) as adjuvant therapy in mCRC patients with LLD after R0/R1 resection...Secondarily resected patients of LICC, CELIM and FIRE-3 showed an impressive median survival with a tendency for improved survival for patients in the LICC trial. A younger patient cohort but also more selective surgery, improved resection techniques, deep responses and a close surveillance program after surgery in the LICC trial may have had a positive impact on survival.
- || Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Review, Journal, Checkpoint inhibition: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. (Pubmed Central) - Jan 7, 2022
The immunological interventions were active immunotherapy Bacillus Calmette-Guérin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25), and targeted natural killer (NK) cells...Two trials provided health-related quality of life results with contradicting results. AUTHORS' Based on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC.
- || cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. (Pubmed Central) - Dec 17, 2021
Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC. Upfront docetaxel did not improve chemotherapy activity or tolerability; these results suggest that upfront neoadjuvant treatment with anthracyclines remains a valid option.
- || Avastin (bevacizumab) / Roche, Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Clinical, P2 data, Journal: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). (Pubmed Central) - Oct 13, 2021
In this selected group of patients, the median progression-free survival and overall survival are encouraging. Given that consolidation immunotherapy is now a standard of care following CRT in patients with LA-NSCLC, these results support a role for continued investigation of antiangiogenic and immunotherapy combinations in LA-NSCLC.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2750;
The majority of research has identified PD-1/PD-L1 immune-checkpoint inhibitors exhibiting favorable toxicity when compared to standard treatment. These modalities have also shown efficacy in NSCLC patients who have failed first-line treatment.
- | Avastin (bevacizumab) / Roche, Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion, Surgery: BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 23, 2020
P2, N=70, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
These modalities have also shown efficacy in NSCLC patients who have failed first-line treatment. Active, not recruiting --> Completed
- || Stimuvax (tecemotide) / EMD Serono, Seattle Genetics
Clinical, P2 data, Journal: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). (Pubmed Central) - Nov 12, 2020
Active, not recruiting --> Completed Neoadjuvant tecemotide is safe, but does not improve RCB or pCR rates in patients receiving standard neoadjuvant therapy.
- || Stimuvax (tecemotide) / EMD Serono, Seattle Genetics, cyclophosphamide intravenous / Generic mfg.
Clinical, P2 data, Journal: Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). (Pubmed Central) - Sep 16, 2020
P2
MUC1 expression was not associated with outcome.EudraCT No: 2011-000218-20Clinical Trial Information: NCT01462513Financial Support: Merck KGaA, Darmstadt, Germany. AE: adverse event; CP: cyclophosphamide; CRC: colorectal cancer; CT: computed tomography; ECOG: Eastern Cooperative Oncology Group; FU: follow-up; HR: hazard ratio; IHC: immunohistochemical staining; ITT: intention-to-treat; DSMB: Data Safety Monitoring Board; LLD: liver-limited disease; mCRC: metastatic colorectal cancer; MPLA: monophosphoryl lipid; AMRI: magnetic resonance imaging; MUC1: mucin 1; NA: not applicable; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NS: normal saline; NSCLC: non-small-cell lung carcinoma; OS: overall surviva; lPP: per protocol; RAS: Rat sarcoma; RFS: recurrence-free survival; TEAE: treatment-emergent adverse event; UICC: Union for International Cancer Control; US: ultrasound; vs.: versus.
- || TG4010 / Transgene, Stimuvax (tecemotide) / EMD Serono, Seattle Genetics, Lucanix (belagenpumatucel-L) / Activate Immunotherapy
Retrospective data, Review, Journal, IO Complimentary Diagnostic: Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis. (Pubmed Central) - Jul 10, 2020
However, these evidences might be limited by potential biases. Therefore, further well-conducted, large-scale RCTs are needed to verify our findings.
- | Imfinzi (durvalumab) / AstraZeneca, BMS, Stimuvax (tecemotide) / EMD Serono, Seattle Genetics
Journal: Role of immunotherapy in stage III nonsmall cell lung cancer. (Pubmed Central) - Feb 14, 2020
PACIFIC trial results are expected to definitely establish durvalumab as standard consolidation strategy in LA-NSCLC. Many clinical trials are ongoing in the field of immunoradiotherapy in LA-NSCLC to define the optimal conditions for this therapeutic combination.
- ||||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
New P2 trial, MSi-H Biomarker, IO biomarker: SPRINT: Tecemotide (L-BLP25) in Rectal Cancer (clinicaltrials.gov) - Jan 3, 2019
P2, N=124, Active, not recruiting, Sponsor: Merck KGaA
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion, Trial completion date: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (clinicaltrials.gov) - Feb 13, 2018
P2, N=122, Completed, Sponsor: Prof. Dr. Carl Schimanski
Many clinical trials are ongoing in the field of immunoradiotherapy in LA-NSCLC to define the optimal conditions for this therapeutic combination. Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
- | Avastin (bevacizumab) / Roche, Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial primary completion date, Surgery: BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 14, 2017
P2, N=55, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 Trial primary completion date: May 2017 --> Jun 2018
- | Avastin (bevacizumab) / Roche, Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed, Trial primary completion date, Surgery: BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 24, 2017
P2, N=55, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: May 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> May 2017
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion, Combination therapy: EMR 63325-015: Tecemotide (L-BLP25) in Prostate Cancer (clinicaltrials.gov) - Feb 16, 2017
P2, N=28, Completed, Sponsor: EMD Serono
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> May 2017 Active, not recruiting --> Completed
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial termination, Trial primary completion date: START2: Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 23, 2015
P3, N=35, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Jul 2015; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment change, Trial termination, Trial primary completion date: INSPIRE: Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (clinicaltrials.gov) - Sep 4, 2015
P3, N=285, Terminated, Sponsor: Merck KGaA
Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Jul 2015; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC N=40 --> 285 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Jun 2015; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial primary completion date: EMR 63325-006: Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease (clinicaltrials.gov) - Aug 19, 2015
P2, N=22, Completed, Sponsor: Merck KGaA
N=40 --> 285 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Jun 2015; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC. Trial primary completion date: Sep 2009 --> Sep 2007
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial termination: EMR 63325-011: Common Safety Follow-up Trial of Tecemotide (L-BLP25) (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=20, Terminated, Sponsor: Merck KGaA
Trial primary completion date: Sep 2009 --> Sep 2007 Active, not recruiting --> Terminated; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.
- |||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion: Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=178, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Terminated; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC. Active, not recruiting --> Completed
- |||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion, MSi-H Biomarker, IO biomarker: SPRINT: Tecemotide (L-BLP25) in Rectal Cancer (clinicaltrials.gov) - Aug 12, 2015
P2, N=124, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment change, Trial primary completion date: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (clinicaltrials.gov) - Jul 14, 2015
P2, N=122, Active, not recruiting, Sponsor: Prof. Dr. Carl Schimanski
Active, not recruiting --> Completed N=159 --> 122 | Trial primary completion date: Sep 2016 --> Dec 2017
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: EMR 63325-015: Tecemotide (L-BLP25) in Prostate Cancer (clinicaltrials.gov) - Feb 20, 2015
P2, N=28, Active, not recruiting, Sponsor: EMD Serono
N=159 --> 122 | Trial primary completion date: Sep 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=48 --> 28 | Trial primary completion date: Aug 2017 --> Sep 2016
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (clinicaltrials.gov) - Dec 24, 2014
P2, N=159, Active, not recruiting, Sponsor: Dr. Carl Schimanski
Recruiting --> Active, not recruiting | N=48 --> 28 | Trial primary completion date: Aug 2017 --> Sep 2016 Recruiting --> Active, not recruiting
- ||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed: Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy (clinicaltrials.gov) - Dec 13, 2014
P1/2, N=178, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed, Enrollment change, Trial primary completion date: EMR 63325-011: Common Safety Follow-up Trial of Tecemotide (L-BLP25) (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=20, Active, not recruiting, Sponsor: Merck KGaA
Completed --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | N=262 --> 20 | Trial primary completion date: Dec 2019 --> May 2015
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed, Enrollment change, Trial primary completion date: INSPIRE: Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (clinicaltrials.gov) - Nov 24, 2014
P3, N=40, Active, not recruiting, Sponsor: Merck KGaA
Enrolling by invitation --> Active, not recruiting | N=262 --> 20 | Trial primary completion date: Dec 2019 --> May 2015 Recruiting --> Active, not recruiting | N=500 --> 40 | Trial primary completion date: May 2020 --> Mar 2015
- ||||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed: Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (clinicaltrials.gov) - Oct 28, 2014
P3, N=1513, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting | N=500 --> 40 | Trial primary completion date: May 2020 --> Mar 2015 Completed --> Active, not recruiting
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed, Enrollment change: START2: Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 15, 2014
P3, N=35, Active, not recruiting, Sponsor: EMD Serono
Completed --> Active, not recruiting Recruiting --> Active, not recruiting | N=1002 --> 35
- ||||||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion: Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (clinicaltrials.gov) - Aug 15, 2014
P3, N=1513, Completed, Sponsor: EMD Serono
Recruiting --> Active, not recruiting | N=1002 --> 35 Active, not recruiting --> Completed
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial primary completion date, Combination therapy: EMR 63325-015: Tecemotide (L-BLP25) in Prostate Cancer (clinicaltrials.gov) - Aug 1, 2014
P2, N=48, Recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Aug 2017
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment change, Trial initiation date, Combination therapy, Metastases: STRIDE - STimulating Immune Response In aDvanced brEast Cancer (clinicaltrials.gov) - Jul 24, 2014
P3, N=16, Terminated, Sponsor: EMD Serono
Trial primary completion date: Jan 2016 --> Aug 2017 N=42 --> 16 | Initiation date: Jun 2009 --> Sep 2009
- |||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion, Enrollment change, Trial primary completion date: Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy (clinicaltrials.gov) - Jul 14, 2014
P1/2, N=205, Completed, Sponsor: Merck KGaA
N=42 --> 16 | Initiation date: Jun 2009 --> Sep 2009 Active, not recruiting --> Completed | N=168 --> 205 | Trial primary completion date: Jun 2016 --> May 2014
- |||||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment open: START2: Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 20, 2014
P3, N=1002, Recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed | N=168 --> 205 | Trial primary completion date: Jun 2016 --> May 2014 Not yet recruiting --> Recruiting
- |||||||||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
New P3 trial: START2: Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 28, 2014
P3, N=1002, Recruiting, Sponsor: EMD Serono
- ||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment change, MSi-H Biomarker, IO biomarker: SPRINT: Tecemotide (L-BLP25) in Rectal Cancer (clinicaltrials.gov) - Jan 28, 2014
P2, N=124, Active, not recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting N=87 --> 124
- ||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed, MSi-H Biomarker, IO biomarker: SPRINT: Tecemotide (L-BLP25) in Rectal Cancer (clinicaltrials.gov) - Jan 28, 2014
P2, N=124, Active, not recruiting, Sponsor: Merck KGaA
N=87 --> 124 Recruiting --> Active, not recruiting
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial withdrawal: FINGERPRINT: Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 24, 2013
P1, N=0, Withdrawn, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment change: FINGERPRINT: Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 24, 2013
P1, N=0, Withdrawn, Sponsor: Merck KGaA
Not yet recruiting --> Withdrawn N=14 --> 0
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
New P1 trial: FINGERPRINT: Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 20, 2012
P1, N=0, Withdrawn, Sponsor: Merck KGaA
- Avastin (bevacizumab) / Roche, Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment open, Surgery: BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 10, 2012
P2, N=55, Recruiting, Sponsor: Eastern Cooperative Oncology Group
N=14 --> 0 Suspended --> Recruiting
- |||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion: EMR 63325-005: Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Aug 7, 2012
P2b, N=171, Completed, Sponsor: Merck KGaA
Suspended --> Recruiting Active, not recruiting --> Completed
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion: EMR 63325-006: Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease (clinicaltrials.gov) - Aug 7, 2012
P2, N=22, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial completion: Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy (clinicaltrials.gov) - Apr 5, 2012
P2, N=34, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment closed: Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy (clinicaltrials.gov) - Mar 4, 2012
P1/2, N=168, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment open: EMR 63325-011: Common Safety Follow-up Trial of Tecemotide (L-BLP25) (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=250, Enrolling by invitation, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- Avastin (bevacizumab) / Roche, Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial initiation date, Surgery: BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 1, 2012
P2, N=55, Recruiting, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Enrolling by invitation Initiation date: Dec 2008 --> Dec 2010
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
New P2 trial, Combination therapy: EMR 63325-015: Tecemotide (L-BLP25) in Prostate Cancer (clinicaltrials.gov) - Dec 19, 2011
P2, N=48, Recruiting, Sponsor: EMD Serono